Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Generalized Pustular Psoriasis or Erythrodermic Psoriasis
NCT02343744Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2015
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of guselkumab in generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of Participants with Treatment Success at 16 weeks. Started Jan 2015; status: completed.
02
Drugs
guselkumab
03
Conditions
generalized pustular psoriasis (GPP)erythrodermic psoriasis (EP)
Beyond the preview
Go deeper on NCT02343744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02343744.